olomoucine has been researched along with Melanoma in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bentke, A; Laidler, P; Małecki, JM; Ostrowska, B | 1 |
| Hajdúch, M; Hanus, J; Hlobílková, A; Kolár, Z; Mihál, V; Nosková, V; Novotný, R; Strnad, M | 1 |
2 other study(ies) available for olomoucine and Melanoma
| Article | Year |
|---|---|
Cytochalasin D, LY294002 and olomoucine synergize in promoting death of melanoma cells through activation of caspase-3 and apoptosis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Caspase 3; Cell Growth Processes; Cell Line, Tumor; Cell Survival; Chromones; Cytochalasin D; Drug Synergism; Enzyme Activation; Humans; In Situ Nick-End Labeling; Kinetin; Melanoma; Morpholines; Skin Neoplasms; Staurosporine; Up-Regulation | 2010 |
Induction of apoptosis and regression of spontaneous dog melanoma following in vivo application of synthetic cyclin-dependent kinase inhibitor olomoucine.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cyclin-Dependent Kinases; Dog Diseases; Dogs; Enzyme Inhibitors; Facial Neoplasms; Kinetin; Male; Melanoma; Purines | 1997 |